Funding for this research was provided by:
National Cancer Institute (P50 CA098252)
Alleghany Health Network-Johns Hopkins Cancer Research Fund (N/A)
Ovarian Cancer Research Fund Alliance (458972)
Received: 25 April 2017
Accepted: 18 July 2017
First Online: 7 August 2017
: Dr. Yemelyanova’s current affiliation is Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX. The opinions and assertions herein are the private views of the authors and do not purport to be official or to reflect the position of the US FDA or any other part of the US Government. This work was not prepared as part of Dr. Seidman’s official government duties.
: The studies herein under waiver of consent were approved by the Johns Hopkins University Institutional Review Board.
: Not applicable.
: Under a licensing agreement between Pontifax/PI Therapeutics and the Johns Hopkins University, Drs. Anchoori and Roden are entitled to royalties on an invention (RA190) described in this article. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its competing interests policies.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.